Advance Search
LIU Xuejian, WU Xia, LI Yuhua. Influence of CD47 expression regulated by PI3K/AKT pathway on the tumor invasiveness of glioblastoma[J]. Journal of Clinical Medicine in Practice, 2020, 24(7): 56-61. DOI: 10.7619/jcmp.202007017
Citation: LIU Xuejian, WU Xia, LI Yuhua. Influence of CD47 expression regulated by PI3K/AKT pathway on the tumor invasiveness of glioblastoma[J]. Journal of Clinical Medicine in Practice, 2020, 24(7): 56-61. DOI: 10.7619/jcmp.202007017
shu

Influence of CD47 expression regulated by PI3K/AKT pathway on the tumor invasiveness of glioblastoma

  • 1. Department of Biglandulous Hemartoma, Shandong Provincial Third Hospital, Ji'nan, Shandong, 250031;

  • 2. Department of Oncology, The Third People's Hospital of Linyi City, Linyi, Shandong, 276023

More Information
  • Received Date: January 10, 2020
    Graphical Abstract
    • Abstract
  • Objective To investigate the effect of CD47 expression regulated by phosphatidylinositol 3-kinase(PI3K)/protein serine threonine kinase(AKT)pathway on the tumor invasiveness of glioblastoma. Methods Thirty samples of glioblastoma brain tissue confirmed by pathology were collected, and 10 normal samples of brain tissues were collected as controls. Effect of low and high expressions of CD47 on the invasiveness of glioblastoma were analyzed. Results CD47 was highly expressed in glioblastoma cells, and low expression of CD47 could significantly inhibit the tumor invasiveness, and high expression of CD47 could significantly promote the tumor invasiveness. CD47 was able to significantly enhance invasiveness of glioblastoma by activating the PI3K/AKT pathway(P<0.05). Conclusion CD47 is highly expressed in glioblastoma cells, and CD47 can significantly enhance invasiveness of glioblastoma by activating the PI3K/AKT pathway.
    • FullText(HTML)
    • References (31)
  • Munshi A. Central nervous system tumors: Spotlight on India[J]. South Asian J Cancer, 2016, 5(3): 146-147.
    Xu Y M, Yuan J, Zhang Z H, et al. Syndecan-1 expression in human glioma is correlated with advanced tumor progression and poor prognosis[J]. Mol Biol Rep, 2012, 39(9): 8979-8985.
    Miller T E, Liau B B, Wallace L C, et al. Transcription elongation factors represent in vivo cancer dependencies in glioblastoma[J]. Nature, 2017, 547(7663): 355-359.
    Baccelli I, Stenzinger A, Vogel V, et al. Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients[J]. Oncotarget, 2014, 5(18): 8147-8160.
    Sun K, Ye L, Liu X P, et al. Expression of CRT and CD47 in Gastric Carcinoma and Their Significanc[J]. Cancer Res Prev Treat, 2019, 46(1): 45-49.
    Chao M P, Alizadeh A A, Tang C, et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia[J]. Cancer Res, 2011, 71(4): 1374-1384.
    Zhang H M, Lu H Q, Xiang L S, et al. HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells[J]. Proc Natl Acad Sci USA, 2015, 112(45): E6215-E6223.
    Parida S, Pal I, Parekh A, et al. GW627368X inhibits proliferation and induces apoptosis in cervical cancer by interfering with EP4/EGFR interactive signaling[J]. Cell Death Dis, 2016, 7: e2154-e2159.
    Lee T K, Cheung V C, Lu P, et al. Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma[J]. Hepatology, 2014, 60(1): 179-191.
    Zhao H, Wang J X, Kong X D, et al. CD47 promotes tumor invasion and metastasis in non-small cell lung cancer[J]. Sci Rep, 2016, 6: 29719-29723.
    Lo J, Lau E Y, So F T, et al. Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma[J]. Liver Int, 2016, 36(5): 737-745.
    Song X S, Shi B, Huang K X, et al. MiR-133a inhibits cervical cancer growth by targeting EGFR[J]. Oncol Rep, 2015, 34(3): 1573-1580.
    Prasad S B, Yadav S S, Das M, et al. PI3K/AKT pathway-mediated regulation of p27(Kip1)is associated with cell cycle arrest and apoptosis in cervical cancer[J]. Cell Oncol(Dordr), 2015, 38(3): 215-225.
    Chao M P, Tang C, Pachynski R K, et al. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy[J]. Blood, 2011, 118(18): 4890-4901.
    Zhao X W, van Beek E M, Schornagel K, et al. CD47-signal regulatory protein-α(SIRPα)interactions form a barrier for antibody-mediated tumor cell destruction[J]. Proc Natl Acad Sci USA, 2011, 108(45): 18342-18347.
    Cioffi M, Trabulo S, Hidalgo M, et al. Inhibition of CD47 effectively targets pancreatic cancer stem cells via dual mechanisms[J]. Clin Cancer Res, 2015, 21(10): 2325-2337.
    Xiao Z Y, Chung H, Banan B, et al. Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma[J]. Cancer Lett, 2015, 360(2): 302-309.
    Baccelli I, Stenzinger A, Vogel V, et al. Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients[J]. Oncotarget, 2014, 5(18): 8147-8160.
    Wang Y H, Xu Z H, Guo S T, et al. Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis[J]. Mol Ther, 2013, 21(10): 1919-1929.
    Ju B H, Huang Y T, Tian J, et al. In vitro application of anti-CD47 monoclonal antibody for targeted therapy of ovarian cancer[J]. Chinese Journal of Clinical Oncology, 2013, 40(8): 440-443.
    Xu J F, Pan X H, Zhang S J, et al. CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models[J]. Oncotarget, 2015, 6(27): 23662-23670.
    Murata T, Ohnishi H, Okazawa H, et al. CD47 promotes neuronal development through Src- and FRG/Vav2-mediated activation of Rac and Cdc42[J]. J Neurosci, 2006, 26(48): 12397-12407.
    Soto-Pantoja D R, Miller T W, Pendrak M L, et al. CD47 deficiency confers cell and tissue radioprotection by activation of autophagy[J]. Autophagy, 2012, 8(11): 1628-1642.
    Chao M P, Tang C, Pachynski R K, et al. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy[J]. Blood, 2011, 118(18): 4890-4901.
    Chao M P, Weissman I L, Majeti R. The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications[J]. Curr Opin Immunol, 2012, 24(2): 225-232.
    Horrigan S K, Reproducibility Project: Cancer Biology. Replication Study: The CD47-signal regulatory protein alpha(SIRPa)interaction is a therapeutic target for human solid tumors[J]. Elife, 2017, 6: e18173-e18183.
    Pan Y, Volkmer J P, Mach K E, et al. Endoscopic molecular imaging of human bladder cancer using a CD47 antibody[J]. Sci Transl Med, 2014, 6(260): 148-159.
    Ma Y J, Lu C, Li C F, et al. Overexpression of HSPA12B protects against cerebral ischemia/reperfusion injury via a PI3K/Akt-dependent mechanism[J]. Biochim Biophys Acta, 2013, 1832(1): 57-66.
    Dong H Q, Zhang X, Dai X N, et al. Lithium ameliorates lipopolysaccharide-induced microglial activation via inhibition of toll-like receptor 4 expression by activating the PI3K/Akt/FoxO1 pathway[J]. J Neuroinflammation, 2014, 11: 140-148.
    Li X H, Huang J, Yuan D M, et al. HSPA12B regulates SSeCKS-mediated astrocyte inflammatory activation in neuroinflammation[J]. Exp Cell Res, 2015, 339(2): 310-319.
    Cheaib B, Auguste A, Leary A. The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges[J]. Chin J Cancer, 2015, 34(1): 4-16.
    • Related Articles

  • Related Articles

    [1]ZHANG Linyuan, ZHANG Jinbo, TAO Yongming, CHANG Yanjun, LIU Weikai. Effects of growth hormone on in vitro fertilization-embryo transfer in patients with polycystic ovary syndrome[J]. Journal of Clinical Medicine in Practice, 2023, 27(4): 48-51. DOI: 10.7619/jcmp.20222139
    [2]SUN Qingqing, ZHANG Guoqing, YANG Yaru, LI Zhenbei, CAO Yijuan, GU Juan. Eddects of different tubal factors on in vitro fertilization embryo transfer[J]. Journal of Clinical Medicine in Practice, 2021, 25(6): 85-88. DOI: 10.7619/jcmp.20201749
    [3]DAI Qijie, TAO Jing, HUA Jianwu, SUN Wei. Occurrence of sarcopenia in maintenance hemodialysis patients and its influencing factors[J]. Journal of Clinical Medicine in Practice, 2020, 24(12): 103-106. DOI: 10.7619/jcmp.202012029
    [4]SHI Jing. Investigation on quality of birth and life of patients with in vitro fertilization-embryo transfer[J]. Journal of Clinical Medicine in Practice, 2020, 24(2): 26-28. DOI: 10.7619/jcmp.202002008
    [5]XIAO Yili, PAN Jianfang, WANG Liping, DUAN Yali. Food allergy status of infants and young children in community in Shanghai and influencing factors[J]. Journal of Clinical Medicine in Practice, 2018, (11): 72-74,78. DOI: 10.7619/jcmp.201811020
    [6]LUO Man, DENG Zhaohui, LONG Huijuan. Comparison on the effect of different ovulation induction programs for polycystic ovary patients with in vitro fertilization-embryo transfer and influence on the expression of related indicators[J]. Journal of Clinical Medicine in Practice, 2017, (17): 76-78. DOI: 10.7619/jcmp.201717022
    [7]TAN Zhihui, TANG Qiqun, CHENG Jie. The status and influencing factors of work values of ICU nurses[J]. Journal of Clinical Medicine in Practice, 2017, (10): 130-133. DOI: 10.7619/jcmp.201710039
    [8]XIONG Dongmei, TIAN Jing, HUANG Xiaodan. Analysis of self nursing ability and influencing factors in tumor patients with PICC[J]. Journal of Clinical Medicine in Practice, 2016, (16): 78-81. DOI: 10.7619/jcmp.201616024
    [9]ZHANG Ping, ZHAO Jing, WANG Yunying, HAN Xiaoyan. Effect of dehidroepiandroszteron on diminished ovarian reserve patients with in vitro fertilization and embryo transfer[J]. Journal of Clinical Medicine in Practice, 2014, (13): 57-59. DOI: 10.7619/jcmp.201413018
    [10]REN Xiuqiong. Perinatal mental state of primiparas and its influencing factors[J]. Journal of Clinical Medicine in Practice, 2014, (10): 122-123,126. DOI: 10.7619/jcmp.201410045

  • Cited by

    Periodical cited type(5)

    1. 孙振普，张建生，冯福梅，何志国，杜海鹏，吴岭. 不同入路腹腔镜胃癌根治术对胃癌患者胃肠功能障碍及肿瘤标志物水平的影响. 医学信息. 2023(21): 110-113 .
    2. 李健. 腹腔镜下胃癌根治术对进展期胃癌的疗效. 河南医学研究. 2021(05): 854-856 .
    3. 李新民. 全腹腔镜下经网膜囊外入路与内入路根治术在胃癌患者中的应用效果比较. 河南医学研究. 2021(35): 6615-6617 .
    4. 梅强. 不同入路全腹腔镜胃癌根治术治疗胃癌的临床效果比较. 实用中西医结合临床. 2021(22): 124-125 .
    5. 何锋，向可，郑露. 腹腔镜辅助胃癌根治手术治疗进展期胃癌的短期疗效观察. 西藏医药. 2020(04): 43-44 .

    Other cited types(2)

Catalog

    Get Citation
    PDF
    XML
    Article views (305) PDF downloads (13) Cited by(7)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return